Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Adam G StarrPaolo F CaimiPingFu FuMira R MassoudHoward MeyersonEric D HsiDavid B MansurSheen CherianBrenda W CooperMarcos J G De LimaHillard M LazarusStanton L GersonDeepa JagadeeshMitchell Reed SmithRobert M DeanBrad L PohlmanBrian T HillBasem M WilliamPublished in: Hematology (Amsterdam, Netherlands) (2017)
Outcomes of SMZL, in our series, were excellent, with a median OS of >13 years. Low hemoglobin and high-risk FLIPI were associated with inferior outcomes.